# US 2004/0023869 A1 · Interleukin-1 inhibitors in the treatment of diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0023869 A1
- Document ID: US20040023869A1
- Status: Published application
- Kind: A1
- Application number: 10/327,215
- Filed: 2002-12-20
- Published: 2004-02-05
- Earliest claimed: 2000-05-12
- Inventors: John E. Sims; Larry F. O'Neal
- Web page: https://patentgrep.com/patent/US20040023869A1

## CPC

- A61K 38/1793: {for cytokines; for lymphokines; for interferons}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 17/00: Drugs for dermatological disorders
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 33/06: Antimalarials
- A61P 35/00: Antineoplastic agents
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention pertains to methods for treating medical disorders characterized by elevated levels or abnormal expression of IL-1 by administering an IL-1 antagonist, such as soluble type II IL-receptor.

## Claims

### Claim 1

A method of treating a patient afflicted with a medical disorder selected from the group consisting of Alzheimer's, stroke, head trauma, myocardial infarction, heart failure, acute coronary syndrome, periodontal disease, inflammatory bowel disease, asthma and pancreatitis, the method comprising administering to said patient a therapeutically effective amount of an IL-1 receptor.

### Claim 2 (depends on 1)

The method of claim 1, wherein the IL-1 receptor is type II IL-1 receptor.

### Claim 3 (depends on 2)

The method of claim 2, wherein the type II IL-1 receptor is administered one or more times per week.

### Claim 4 (depends on 2)

The method of claim 2, wherein type II IL-1 receptor is administered by subcutaneous injection.

### Claim 5

A method of treating a patient afflicted with stroke, the method comprising administering to the patient a therapeutically effective amount of type II IL-1 receptor.

### Claim 6 (depends on 5)

The method of claim 5 wherein the type II IL-1 receptor is administering intracranially.

### Claim 7

A method of treating a patient afflicted with heart failure, the method comprising administering to the patient a therapeutically effective amount of type II IL-1 receptor.

### Claim 8 (depends on 2)

The method of claim 2, wherein the type II IL-1 receptor is administered in combination with one or more compounds selected from the group consisting of non-steroidal anti-inflammatory drugs; analgesics; topical steroids; systemic steroids; antagonists of inflammatory cytokines; antibodies against T cell surface proteins; anthralin; coal tar; vitamin D3 and its analogs; topical retinoids; oral retinoids; salicylic acid; methotrexate; cyclosporine; hydroxyurea; and sulfasalazine.

### Claim 9 (depends on 2)

The method of claim 2, wherein the soluble type II IL-1 receptor is administered in combination with a TNF inhibitor.

### Claim 10 (depends on 9)

The method of claim 9 wherein the TNF inhibitor is TNFR: Fe.

### Claim 11 (depends on 2)

The method of claim 2, wherein the type II IL-1 receptor is administered in combination with a compound selected from the group consisting of antagonists of IFNγ, TGFβ, IL-6 and IL-8.

### Claim 12 (depends on 9)

The method of claim 9 wherein the soluble type II IL-1 receptor and TNF inhibitor are administered in combination with a compound selected from the group consisting of antagonists of IFNγ, TGFβ, IL-6 and IL-8.
